Immunotherapy for Lung Cancer

被引：13

作者：

Reinmuth, Niels ^{[1
]}

Reck, Martin ^{[2
]}

机构：

[1] Fachklin Gauting, Dept Thorac Oncol, Gauting, Germany

[2] Airway Res Ctr North, LungenClin, Dept Thorac Oncol, Grosshansdorf, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 06期

关键词：

Immunotherapy; Lung cancer; ANTI-PD-L1; ANTIBODY; ANTITUMOR-ACTIVITY; IPILIMUMAB; NIVOLUMAB; SAFETY; MULTICENTER; DOCETAXEL; BLOCKADE;

D O I：

10.1159/000446726

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Immune evasion is recognized as a key strategy for cancer survival and progression. Hence, various approaches to restore antitumor immune responses are currently being investigated. In particular, agents targeting immune checkpoints, such as the cytotoxic T-lymphocyte-associated antigen-4 receptor and programmed death-1 receptor, have shown potential for improving tumor responses and survival in lung cancer patients. With the first immunomodulating agents having been approved for treatment of selected lung cancer patients, there are high expectations that treatment outcomes may be improved with the incorporation of immunotherapies into the various treatment cascades. (C) 2016 S. Karger GmbH, Freiburg

引用

页码：360 / 368

页数：7

共 38 条

[1]

[Anonymous], J CLIN ONCOL S

[2]

Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[3]

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. [J].

Antonia, Scott Joseph ;

Gettinger, Scott N. ;

Chow, Laura Quan Man ;

Juergens, Rosalyn A. ;

Borghaei, Hossein ;

Shen, Yun ;

Harbison, Christopher ;

Chen, Allen C. ;

Ready, Neal ;

Rizvi, Naiyer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[4]

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5]

Immunotherapy for lung cancer [J].

Bradbury, Penelope A. ;

Shepherd, Frances A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) :S164-S170

[6]

Brahmer JR, 2014, J CLIN ONCOL, V32, P8021, DOI DOI 10.1200/jco.2014.32.15_suppl.8021

[7]

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[8]

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[9]

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer [J].

Butts, C ;

Murray, N ;

Maksymiuk, A ;

Goss, G ;

Marshall, E ;

Soulières, D ;

Cormier, Y ;

Ellis, P ;

Price, A ;

Sawhney, R ;

Davis, M ;

Mansi, J ;

Smith, C ;

Vergidis, D ;

Ellis, P ;

MacNeil, M ;

Palmer, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6674-6681

[10]

Chasalow SD, 2012, ANN ONCOL, V23, P75

← 1 2 3 4 →